Supplementary Data 1 from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Tables, Figures, and References
Authors: Vivek Subbiah, Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony Tolcher, Nehal J. Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim Hussain, Carson Veldstra, James Kalabus, Brianne O’Neill, Lane Senne, Emily Rowell, Analeah B. Heidt, Katelyn M. Willis, Brendan P. Eckelman
Language: English
Subfield: Orthopedics and Sports Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4385836760